ZNF282 (Zinc finger protein 282), a novel E2F1 co-activator, promotes esophageal squamous cell carcinoma

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12260-12272

  Yeo, So Young ^a   Ha, Sang Yun ^b   Yu, Eun Ji ^a   Lee, Keun Woo ^a   Kim, Jeong Hoon ^a,c   Kim, Seok Hyung ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Cell cycle; E2F1; Esophageal squamous cell carcinoma; Prognosis; ZNF282

Indexed keywords

TUMOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN 282; COENZYME; DNA BINDING PROTEIN; E2F1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR E2F1; ZINC FINGER PROTEIN;

AGE DISTRIBUTION; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMBRYO; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR PROMOTION; ANIMAL; APOPTOSIS; CELL MOTION; CHROMATIN IMMUNOPRECIPITATION; COENZYME; ESOPHAGUS TUMOR; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; WESTERN BLOTTING; XENOGRAFT;

AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CHROMATIN IMMUNOPRECIPITATION; COENZYMES; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TRANSFECTION; ZINC FINGERS;

EID: 84920008476     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2630     Document Type: Article

References (30)

1. Fred T. Bosman FC, Ralph H. Hruban, Neil D. Theise. (2009). WHO classification of tumours of the digestive system. (Lyon: International Agency of Reserach on Cancer).
2. Hongo M, Nagasaki Y and Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009; 24: 729-735.
3. Lao-Sirieix P and Fitzgerald RC. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012; 9: 278-287.
4. Klein CA and Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res. 2009; 69: 5285-5288.
5. Bird-Lieberman EL and Fitzgerald RC. Early diagnosis of oesophageal cancer. Br J Cancer. 2009; 101: 1-6.
6. Okumura K, Sakaguchi G, Naito K, Tamura T and Igarashi H. HUB1, a novel Kruppel type zinc finger protein, represses the human T cell leukemia virus type I long terminal repeat-mediated expression. Nucleic Acids Res. 1997; 25: 5025-5032.
7. Yu EJ, Kim SH, Kim MJ, Seo WY, Song KA, Kang MS, Yang CK, Stallcup MR and Kim JH. SUMOylation of ZFP282 potentiates its positive effect on estrogen signaling in breast tumorigenesis. Oncogene. 2013; 32: 4160-4168.
8. Lee TI and Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013; 152: 1237-1251.
9. He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY, Zeng YX and Xie D. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100: 1591-1596.
10. Kim SH, Kim JH, Yu EJ, Lee KW and Park CK. The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis. Histol Histopathol. 2012; 27: 49-58.
11. Li Y, Yang HX, Luo RZ, Zhang Y, Li M, Wang X and Jia WH. High expression of p300 has an unfavorable impact on survival in resectable esophageal squamous cell carcinoma. Ann Thorac Surg. 2011; 91: 1531-1538.
12. Lv J, Cao XF, Ji L, Zhu B, Wang DD, Tao L and Li SQ. Association of beta-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma. Med Oncol. 2012; 29: 151-160.
13. Xu FP, Xie D, Wen JM, Wu HX, Liu YD, Bi J, Lv ZL, Zeng YX and Guan XY. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett. 2007; 245: 69-74.
14. Lin DC, Du XL and Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus. 2009; 22: 9-20.
15. Yamazaki K, Hasegawa M, Ohoka I, Hanami K, Asoh A, Nagao T, Sugano I and Ishida Y. Increased E2F-1 expression via tumour cell proliferation and decreased apoptosis are correlated with adverse prognosis in patients with squamous cell carcinoma of the oesophagus. J Clin Pathol. 2005; 58: 904-910.
16. Huang JX, Shen SL, Lin M, Xiao W, Chen WC, Lin MS, Yu H, Chen P and Qian RY. Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2012; 4: 607-611.
17. Engelmann D and Putzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012; 72: 571-575.
18. Hu N, Clifford RJ, Yang HH, Wang C, Goldstein AM, Ding T, Taylor PR and Lee MP. Genome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinoma. BMC Genomics. 2010; 11: 576.
19. Sherr CJ. Cancer cell cycles. Science. 1996; 274: 1672-1677.
20. Munro S, Carr SM and La Thangue NB. Diversity within the pRb pathway: is there a code of conduct? Oncogene. 2012; 31: 4343-4352.
21. Biswas AK and Johnson DG. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res. 2012; 72: 13-17.
22. Wong JV, Dong P, Nevins JR, Mathey-Prevot B and You L. Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle. 2011; 10: 3086-3094.
23. Xiang J, Zang W, Che J, Chen K and Hang J. Regulation network analysis in the esophageal squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2012; 16: 2051-2056.
24. Ebihara Y, Miyamoto M, Shichinohe T, Kawarada Y, Cho Y, Fukunaga A, Murakami S, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Okushiba S, Kondo S and Katoh H. Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus. 2004; 17: 150-154.
25. Mega S, Miyamoto M, Ebihara Y, Takahashi R, Hase R, Li L, Shichinohe T, Kawarada Y, Uehara H, Kaneko H, Hashimoto H, Murakami Y, Itoh T, Morikawa T and Kondo S. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis Esophagus. 2005; 18: 109-113.
26. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX and Chen HW. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol. 2010; 30: 5260-5272.
27. Lee KW, Kim JH, Han S, Sung CO, Do IG, Ko YH, Um SH and Kim SH. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Ann Surg Oncol. 2012; 19: 326-335.
28. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55: 237-241.
29. Kim JH, Yang CK, Heo K, Roeder RG, An W and Stallcup MR. CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell. 2008; 31: 510-519.
30. Yang CK, Kim JH, Li H and Stallcup MR. Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1. J Biol Chem. 2006; 281: 3389-3397.